SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 cents.
The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.
For the year, the company reported that its loss narrowed to $257.7 million, or $1.32 per share. Revenue was reported as $22,000.
In the final minutes of trading on Thursday, the company's shares hit $1.89. A year ago, they were trading at $4.88.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO
/Quantum%20Computing/Image%20by%20Funtap%20via%20Shutterstock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Nike%2C%20Inc_%20shopping%20by-%20hapabapa%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20with%20a%20brain%20on%20top%20of%20a%20blue%20circuit%20board_%20Image%20by%20Gorodenkoff%20via%20Shutterstock_.jpg)
